MiMedx Group (MDXG) Delivers Record Full Year Revenue

Core Insights - MiMedx Group, Inc. (NASDAQ:MDXG) has reported record quarterly and full-year revenue and profitability, driven by strong performance in its wound care and surgical segments, both achieving double-digit growth [1] Financial Performance - In Q4, the company achieved a revenue of $118.1 million, reflecting a year-over-year growth of 27.11%, exceeding market expectations by $11.32 million [2] - The earnings per share (EPS) for Q4 was $0.10, surpassing expectations by $0.01 [2] - The wound care segment grew by 28% year-over-year, while the surgical segment revenue increased by 25% [2] - Gross profit margins improved by 200 basis points to 86% for Q4, attributed to a better product mix compared to the previous year [2] Future Outlook - For fiscal 2026, the company anticipates revenue in the range of $340 million to $360 million, with an adjusted EBITDA margin expected to be in the mid to high teens [3] - MiMedx Group specializes in developing and distributing advanced placental tissue allografts for wound care, surgical, and burn applications, utilizing proprietary processing methods to assist clinicians in treating chronic and hard-to-heal wounds [3]